美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Renaissance International IPO ETF

22.10

+0.12110.55%

成交量：1,314

成交額：2.90萬

市值：1,104.75萬

市盈率：- -

高：22.14

開：22.05

低：22.02

收：21.97

52周最高：26.25

52周最低：15.65

股本：50.00萬

流通股本：50.00萬

量比：0.59

換手率：0.26%

股息：0.14

股息率：0.65%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

恒瑞創新藥凝血因子XI單抗SHR-2004注射液用於擇期膝關節置換手術後成年患者靜脈血栓預防的上市申請獲受理

非息收入僅增0.23%，9家上市股份行忙了個「寂寞」？代理業務冰火兩重天，財富回暖為何沒能帶動中收？

恒瑞醫藥：SHR-2004注射液上市許可申請獲受理

每日经济新闻

恒瑞醫藥：SHR-2004注射液上市許可申請獲受理

海柔創新再度向港交所主板遞表聯席保薦為高盛與中信證券

观点地产网

華海藥業：阿哌沙班片獲得德國上市許可

豐收開新局實幹促振興 | 海門無花果上市銷售

【美股盤前】AI發展放緩呼聲引發市場擔憂，芯片與存儲股集體下跌，英偉達下跌2.5%，英特爾、AMD跌超5%；高管稱波士頓動力IPO條件尚不成熟；沙特管道遇襲停運，布油升逾3%

每日经济新闻

上周無新增IPO受理企業

眾鑫股份：93.07萬股戰略配售限售股將上市流通

AI 計算網絡製造商 Ligent Technologies 計劃在香港進行 IPO，合計募資最高達 57 億港元

正裕工業：3568.60萬股定增限售股9月21日上市流通

據報OpenAI明確今年不會推進上市

波士頓動力2027年IPO料難成行人形機器人商業化前路漫漫

瓦軸B(200706.SZ)：向深圳證券交易所提出終止上市申請

宇樹科技跌1.49%創新低上個月上市募資61億元

超900元/桶！原油再破上市新高，強在哪了？

萊美藥業(300006.SZ)子公司非奈利酮原料藥獲批上市

瓦軸B：擬向深交所申請主動終止股票上市

辰欣藥業(603367.SH)子公司藥品氯替潑諾妥布黴素滴眼液首仿獲批上市

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/IPOS/news?page=18"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IPOS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPOS\",,,,,undefined,":{"symbol":"IPOS","market":"US","secType":"STK","nameCN":"Renaissance International IPO ETF","latestPrice":22.095,"timestamp":1789675200000,"preClose":21.9739,"halted":0,"volume":1314,"delay":0,"changeRate":0.005511083603729808,"floatShares":500001,"shares":500001,"eps":0,"marketStatus":"盤前交易","change":0.1211,"latestTime":"09-18 05:44:50 EDT","open":22.05,"high":22.135,"low":22.02,"amount":29033,"amplitude":0.005233,"askPrice":35.13,"askSize":100,"bidPrice":9.9,"bidSize":14,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789738200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":22.095,"sharesOutstanding":400001,"nav":22.174631,"aum":11087337.73,"dividendRate":0.006499,"bidAskSpread":0.005081,"postHourTrading":{"tag":"盘后","latestPrice":22.08,"preClose":22.095,"latestTime":"16:10 EDT","volume":7,"amount":154.665,"timestamp":1789675804188,"change":-0.015,"changeRate":-0.000679,"amplitude":0},"volumeRatio":0.5917319803223988,"impliedVol":0.8873,"impliedVolPercentile":0.984},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPOS\",,,,,undefined,":{"symbol":"IPOS","floatShares":500001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5917319803223988,"shares":500001,"dividePrice":0.1436,"high":22.135,"amplitude":0.005233,"preClose":21.9739,"low":22.02,"week52Low":15.65,"pbRate":"--","week52High":26.25,"institutionHeld":0,"latestPrice":22.095,"committee":-0.754386,"eps":0,"divideRate":0.006499,"volume":1314,"delay":0,"ttmEps":0,"open":22.05,"prevYearClose":16.8936,"prevWeekClose":22.665,"prevMonthClose":23.3188,"prevQuarterClose":25.635,"fiveDayClose":22.79,"twentyDayClose":23.245,"sixtyDayClose":24.9685},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IPOS\",params:#limit:5,,,undefined,":[{"date":"2026-09-11","symbol":"IPOS","amount":0.072205,"announcedDate":"2026-09-10","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-11","defaultRemindTime":1789133400000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-11","currency":"USD","dateTimestamp":1789099200000,"payDate":"2026-09-18"},{"date":"2026-06-12","symbol":"IPOS","amount":0.054103,"announcedDate":"2026-06-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-12","defaultRemindTime":1781271000000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-22","payableDate":"2026-06-12","currency":"USD","dateTimestamp":1781236800000,"payDate":"2026-06-22"},{"date":"2025-12-12","symbol":"IPOS","amount":0.017941,"announcedDate":"2025-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-12","defaultRemindTime":1765549800000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-12","currency":"USD","dateTimestamp":1765515600000,"payDate":"2025-12-19"},{"date":"2025-09-12","symbol":"IPOS","amount":0.007352,"announcedDate":"2025-09-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-12","defaultRemindTime":1757683800000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-12","currency":"USD","dateTimestamp":1757649600000,"payDate":"2025-09-19"},{"date":"2025-06-13","symbol":"IPOS","amount":0.13555,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-13","defaultRemindTime":1749821400000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-13","currency":"USD","dateTimestamp":1749787200000,"payDate":"2025-06-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IPOS\",market:\"US\",,,undefined,":[{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.15245,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-22","value":0.05857,"currency":"USD"},{"executeDate":"2018-03-16","recordDate":"2018-03-19","paymentDate":"2018-03-23","value":0.00775,"currency":"USD"},{"executeDate":"2018-06-15","recordDate":"2018-06-18","paymentDate":"2018-06-22","value":0.2024,"currency":"USD"},{"executeDate":"2018-12-14","recordDate":"2018-12-17","paymentDate":"2018-12-21","value":0.80265,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IPOS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IPOS\",pageSize:20,pageCount:18,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667657738","title":"恒瑞創新藥凝血因子XI單抗SHR-2004注射液用於擇期膝關節置換手術後成年患者靜脈血栓預防的上市申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657738","media":"恒瑞医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657738?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:59","pubTimestamp":1789379940,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药子公司北京盛迪医药有限公司收到国家药监局下发的《受理通知书》，公司1类创新药、凝血因子XI单克隆抗体SHR-2004注射液的药品上市许可申请获受理，拟定适应症为：用于择期膝关节置换手术的成年患者，以预防静脉血栓形成。该研究旨在评价行择期TKA的患者使用SHR-2004注射液预防静脉血栓栓塞症的有效性和安全性。此外，SHR-2004用于卵巢癌术后VTE预防的Ⅱ期试验已完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-14/doc-iniruxuy4531842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","159992","IBBQ","06978","IPOS","BK1574","LNGR","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667965773","title":"非息收入僅增0.23%，9家上市股份行忙了個「寂寞」？代理業務冰火兩重天，財富回暖為何沒能帶動中收？","url":"https://stock-news.laohu8.com/highlight/detail?id=2667965773","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667965773?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:54","pubTimestamp":1789379640,"startTime":"0","endTime":"0","summary":"部分银行的财富管理相关收入恢复较快，譬如民生银行，该行上半年代理业务手续费增长64.92%；另外，招行代理基金手续费增长61.40%，平安银行代理及委托手续费增长27.6%。今年上半年，9家股份行中，6家非息收入正增长，3家负增长。因此，非息收入增长或下降，并不能简单等同于中收的同步变化。代理业务表现“冰火两重天”进一步拆分手续费收入，财富管理业务的变化更为明显。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/bank/gsdt/2026-09-14/doc-iniruxuu7251063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667265224","title":"恒瑞醫藥：SHR-2004注射液上市許可申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2667265224","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667265224?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:49","pubTimestamp":1789379352,"startTime":"0","endTime":"0","summary":"9月14日，恒瑞医药公告称，公司子公司北京盛迪医药收到国家药监局下发的《受理通知书》，公司1类创新药、凝血因子XI单克隆抗体SHR-2004注射液的药品上市许可申请获受理。该药品拟定适应症为用于择期膝关节置换手术的成年患者，以预防静脉血栓形成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873526173.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873526173.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201612.USD","LU0405327148.USD","LU2289578879.USD","BK0188","LU1064131003.USD","LU0405327494.USD","600276","LU1781817850.SGD","LU2148510915.USD","BK1191","LU0359201885.HKD","LU1655091616.SGD","LU1997244956.HKD","BK0239","LU1146622755.USD","LU2097828805.USD","LU2543165471.USD","LU2097828714.EUR","01276","LU1969619763.USD","LU1580142542.USD","LU0359202008.SGD","LU2580892862.HKD","BK0028","LU1023057109.AUD","LU2097828631.EUR","IPOS","LU1064130708.USD","LU2488822045.USD","LU2097828474.EUR","LU1820825898.SGD","BK0012","LU2328871848.SGD","LU2580892789.USD","LU1997245094.SGD","BK0183","LU2495084118.USD","BK0060","BK0196","LU2097828557.USD","LU1255011170.USD","LU1997245177.USD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667652502","title":"恒瑞醫藥：SHR-2004注射液上市許可申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2667652502","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667652502?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:46","pubTimestamp":1789379185,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667650823","title":"海柔創新再度向港交所主板遞表 聯席保薦為高盛與中信證券","url":"https://stock-news.laohu8.com/highlight/detail?id=2667650823","media":"观点地产网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667650823?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:43","pubTimestamp":1789378980,"startTime":"0","endTime":"0","summary":"观点网讯：9月13日，深圳市海柔创新智慧科技集团股份有限公司向港交所主板递交上市申请，联席保荐人为高盛、中信证券。招股书显示，海柔创新是一家仓储自动化领域的企业，专注于拣选自动化解决方案，拣选是仓库中最为劳动密集及耗时的活动。此次为该公司再度递表。海柔创新曾于今年2月13日向港交所递交上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/estate/integration/2026-09-14/doc-iniruxuw3993623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1328615791.USD","BK1516","BK0012","LU1064131003.USD","IE00B19Z3581.USD","LU1781817850.SGD","BK0028","HEXmain","LU2237443465.HKD","IE0004091025.USD","LU0345770308.USD","LU1255011170.USD","LU0106831901.USD","600030","06030","LU1720050803.USD","LU0868494708.USD","BK1521","LU1655091616.SGD","LU2237443382.USD","BK4127","LU0061475181.USD","LU1146622755.USD","BK0183","LU0345770993.USD","IE0002270589.USD","LU1668664300.SGD","LU1997245177.USD","LU2237443549.SGD","LU2471134879.HKD","IE00B19Z3B42.SGD","LU0942090050.USD","LU1997244956.HKD","LU0742534661.SGD","BK1147","LU1580142542.USD","LU2148510915.USD","BK4552","BK4585","BK4550","GSX","LU0251142724.SGD","LU1894683264.USD","LU0048573561.USD","IPOS","LU1868836591.USD","LU1868836914.USD","LU2237438978.USD","LU2471134796.USD","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654723","title":"華海藥業：阿哌沙班片獲得德國上市許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654723","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667654723?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:39","pubTimestamp":1789378774,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667765221","title":"豐收開新局 實幹促振興 | 海門無花果上市銷售","url":"https://stock-news.laohu8.com/highlight/detail?id=2667765221","media":"江川发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667765221?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:36","pubTimestamp":1789378560,"startTime":"0","endTime":"0","summary":"在成熟上市周期方面，基地无花果每年8月底开始陆续成熟，进入初采阶段，可供少量采摘与销售；每年9月15日后果实进入集中成熟期，大批量鲜果可上市供应，能够精准对接秋季鲜果市场需求，抢占市场销售窗口期。产量方面，基地无花果产量呈逐年稳步递增的丰产态势，种植收益稳定可期。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-14/doc-iniruxus9352664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667523116","title":"【美股盤前】AI發展放緩呼聲引發市場擔憂，芯片與存儲股集體下跌，英偉達下跌2.5%，英特爾、AMD跌超5%；高管稱波士頓動力IPO條件尚不成熟；沙特管道遇襲停運，布油升逾3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667523116","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667523116?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:32","pubTimestamp":1789378366,"startTime":"0","endTime":"0","summary":"①【三大期指齐跌】截至发稿，道指期货跌0.18%，标普500指数期货跌0.69%，纳指期货跌1.72%。②【AI发展放缓呼声引发市场担忧，芯片与存储股集体下跌】9月12日，AnthropicCEO达里奥·阿莫代伊（DarioAmodei）发表文章，呼吁业界放缓AI模型的开发节奏，引发投资者广泛关注。阿莫代伊在文章中提出了一项“放缓前沿竞争”的计划。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873505440.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873505440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["FDTX","ARTY","SOXL","NVDA","SOXS","LFGY","LEGR","SOXY","DBO","AIS","LINT","PSI","QTOC","AGOX","CHAT","VTHR","CLSE","FTXL","INTC","EFIV","SSG","TEKX","UCO","ESLG","CHPS","CNEQ","USD","SOXQ","AMD","SNPE","REDS","THMR","XSD","FRHC","AGIX","SOXX","USO","TTEQ","159813","KCE","AIPO","IPOS","SMH","CNAV","TTXU","CHPY","GFS","SMHX","SCO","NVIW.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667693654","title":"上周無新增IPO受理企業","url":"https://stock-news.laohu8.com/highlight/detail?id=2667693654","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667693654?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:25","pubTimestamp":1789377948,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FRHC","IPOS","BK4127","REDS","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654698","title":"眾鑫股份：93.07萬股戰略配售限售股將上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654698","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667654698?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:25","pubTimestamp":1789377937,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654275","title":"AI 計算網絡製造商 Ligent Technologies 計劃在香港進行 IPO，合計募資最高達 57 億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654275","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667654275?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:23","pubTimestamp":1789377827,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据彭博社报道，AI 计算网络制造商 Ligent Technologies Inc. 计划在香港进行 IPO，拟发行 1.72 亿股股票，发行价每股 32.96 港元，合计募资最高达 57 亿港元（约 7.27 亿美元）。该公司总部位于美国加州圣何塞，为中资背景企业。股票预计于 9 月 22 日正式挂牌交易。 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2289637","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","BK4127","AGIX","CHAT","IPOS","QTOC","VTHR","ARTY","REDS","AIPO","FRHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667565482","title":"正裕工業：3568.60萬股定增限售股9月21日上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2667565482","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667565482?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:18","pubTimestamp":1789377534,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667651054","title":"據報OpenAI明確今年不會推進上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2667651054","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667651054?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:05","pubTimestamp":1789376755,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据外媒报道，OpenAI首席执行官萨姆·阿尔特曼在周末接受采访时明确指出，ChatGPT的母公司OpenAI今年不会进行首次公开募股（IPO），并直接回应称在当前的评估阶段推进上市是“不明智的”。阿尔特曼随后在社交平台X上进一步解释，前沿人工智能的研发需要循序渐进，而非盲目冲刺或停滞不前。该表态反映了近期AI行业领袖对安全性和负责任研发的共同诉求。有分析人士认为，投资者此前对AI领军企业的资本运作寄予厚望。OpenAI延缓上市进程，加上市场对行业研发速度放缓及合规成本上升的担忧，直接打压了风险偏好。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305983","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667597216","title":"波士頓動力2027年IPO料難成行 人形機器人商業化前路漫漫","url":"https://stock-news.laohu8.com/highlight/detail?id=2667597216","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667597216?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:41","pubTimestamp":1789375273,"startTime":"0","endTime":"0","summary":"现代汽车集团尚未公开披露波士顿动力潜在上市的时间表或估值目标。集团未立即回应置评请求，波士顿动力在非营业时间亦无法置评。IPO或仍需数年分析师认为，波士顿动力未来几年不太可能上市，因人形机器人仍无法在工厂广泛部署。文件显示，2021年至2025年，波士顿动力累计亏损近1.7万亿韩元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4127","KCE","ROBT","FRHC","UBOT","WDRN","REDS","RTOO","PBOT","IQM","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695651","title":"瓦軸B(200706.SZ)：向深圳證券交易所提出終止上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695651","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695651?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:37","pubTimestamp":1789375022,"startTime":"0","endTime":"0","summary":"格隆汇9月14日丨瓦轴B(200706.SZ)公布，根据中国证券登记结算有限责任公司深圳分公司的统计，截至2026年2月27日，瓦轴B预受要约的股东为1,459户，预受要约的无限售条件流通社会公众股份数量合计54,524,555股。根据《瓦房店轴承股份有限公司要约收购报告书》约定的生效条件，本次要约收购生效。\n\n　　在本次预受要约股份过户完成后，由于社会公众持有的股份数量占公司股份总数比例低于10%，根据《证券法》《深圳证券交易所股票上市规则》等相关法规的规定,公司的股权分布已不再具备上市条件。根据相关法规的规定，公司向深圳证券交易所提出终止上市的申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260914/32369058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","399001"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667665643","title":"宇樹科技跌1.49%創新低 上個月上市募資61億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667665643","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667665643?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:17","pubTimestamp":1789373822,"startTime":"0","endTime":"0","summary":"中国经济网北京9月14日讯 宇树科技 今日盘中最低报465.58元，创上市以来股价新低。截至今日收盘，宇树科技报470元，跌幅1.49%。宇树科技上市首日开盘报1100元，若以上市当日开盘价买入宇树科技，今日收盘时亏损57.27%。　　宇树科技2026年8月19日在上交所科创板上市，发行股票数量4,044.6434万股，发行价格为150.80元/股。　　宇树科技本次发行募集资金总额609,932.22万元；扣除发行费用后，募集资金净额为591,714.92万元。宇树科技最终募集资金净额较原计划多171,543.8万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260914/32369038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667596816","title":"超900元/桶！原油再破上市新高，強在哪了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2667596816","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667596816?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:17","pubTimestamp":1789373820,"startTime":"0","endTime":"0","summary":"风险提示油价的波动还有可能进一步上升，交易者应严控风险，谨慎参与。受到地缘冲突升级的影响，国内原油价格大幅上行，截至9月14日收盘，SC原油价格最高至910元/桶，创下了自2018年3月26日上市以来的最高价，初步估算溢价同时刻的Brent价格约25美元/桶，SC为何如此强？9月11日前后，沙特宣布因遭受无人机的袭击，东西管线预防性停输。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/future/2026-09-14/doc-inirutpa4609441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IEO","FAAR","BNO","SCO","BK4570","DDG","PXE","IPOS","FTXN","DUG","BK4588","OILK","USOI","DBO","USL","DBE","USO","DRLL","XOP","OIH","OILT","DRIP","VDE","WTIU","FBZ","GUSH","BK4585","IXC","CLmain","OILU","ERX","USE","FLBR","MCLmain","DIG","DWT","UGA","XES","PXJ","DBC","QMmain","BZmain","UCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667327659","title":"萊美藥業(300006.SZ)子公司非奈利酮原料藥獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2667327659","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667327659?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:14","pubTimestamp":1789373691,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莱美药业(300006.SZ)发布公告，近日，公司全资子公司重庆莱美隆宇药业有限公司(简称莱美隆宇)收到国家药品监督管理局核准签发的非奈利酮《化学原料药上市申请批准通知书》。非奈利酮是一种非甾体选择性盐皮质激素受体(MR)拮抗剂，其制剂用于治疗与2型糖尿病相关的慢性肾病成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0070","300006","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659880","title":"瓦軸B：擬向深交所申請主動終止股票上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659880","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667659880?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:14","pubTimestamp":1789373664,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656246","title":"辰欣藥業(603367.SH)子公司藥品氯替潑諾妥布黴素滴眼液首仿獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656246","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656246?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:05","pubTimestamp":1789373101,"startTime":"0","endTime":"0","summary":"智通财经APP讯，辰欣药业(603367.SH)发布公告，近日，公司子公司山东辰欣佛都药业股份有限公司(简称“佛都药业”)收到国家药品监督管理局核准签发的氯替泼诺妥布霉素滴眼液《药品注册证书》。氯替泼诺妥布霉素滴眼液注册分类为化学药品4类，主要用于治疗对类固醇有反应的眼部炎症，及其伴随的或潜在的眼表面细菌感染。佛都药业氯替泼诺妥布霉素滴眼液首次提交注册申请获得受理的时间为2025年，本次为国内首仿上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK0239","603367"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":52,"pageCount":18,"totalSize":1035,"code":"91000000","status":"200"}]}}